Kerry Lutz's--Financial Survival Network

MAIA Biotechnology's Ateganosine Shows 88% Disease Control Rate in Phase Two Lung Cancer Trial

10 min Listen to the original Episode page
OncologyClinical TrialsImmunotherapyBiotechnologyFDA Orphan Drug DesignationLung CancerTelomerasePhase 2 Results

Summary

Host Kerry Lutz interviews Dr. Vlad Vitoc of MAIA Biotechnology about ateganosine (THIO), a cancer therapy targeting telomerase. Dr. Vitoc explains the drug's dual mechanism of direct telomere collapse and immune system activation via neoantigen presentation. The FDA has granted orphan drug designations for liver, small cell lung, brain, and pediatric brain cancers. Phase Two results in third-line non-small cell lung cancer showed an 88% disease control rate and 17.8-month median survival versus chemotherapy's 25-35% and 5.8 months. The company is currently enrolling in Phase Three trials.

Key takeaways

  1. 1
    Median overall survival was 17.8 months for ateganosine compared to 5.8 months for chemotherapy in the same patient population.

    Unidentified speaker (speaker_2) · 7:08

Episode sections

  1. 0:00 – 1:12

    Introduction and Drug Mechanism Overview

    Host Kerry Lutz introduces Dr. Vlad Vitoc of MAIA Biotechnology to discuss ateganosine (THIO), a cancer therapy with a dual mechanism of telomere targeting and immunogenicity. Dr. Vitoc explains that the drug targets telomeres, the protective caps of chromosomes, which shorten with cell division in healthy cells but are maintained by telomerase in cancer cells.

  2. 1:12 – 3:40

    Telomerase Biology and Drug Action

    Dr. Vitoc details how telomerase is reactivated in cancer cells to grant replicative immortality. Ateganosine, a guanosine analog, is picked up by telomerase and inserted into telomeres, causing them to collapse and DNA to unwind, leading to cancer cell death within 24-72 hours.

  3. 3:40 – 4:55

    Immune System Activation and FDA Designations

    The drug forms micronuclei that present tumor fragments as neoantigens, triggering an immune response. When combined with checkpoint inhibitors, this can lead to complete response and immune memory. The FDA granted ateganosine orphan drug designations for liver cancer, small cell lung cancer, brain cancer, and a rare pediatric brain cancer.

  4. 4:55 – 6:00

    Telomerase Prevalence in Cancers

    Dr. Vitoc confirms that over 85% of human cancers rely on telomerase, with some types like small cell lung cancer at 100%. He compares the potential impact of this mechanism to the launch of Keytruda, noting its broad applicability across tumor types.

  5. 6:00 – 7:51

    Phase Two Results and Phase Three Progress

    The speakers discuss Phase Two results showing an 88% disease control rate and 17.8-month median overall survival in third-line non-small cell lung cancer patients, compared to 25-35% disease control and 5.8-month survival with chemotherapy. The company is now enrolling in Phase Three trials.

  6. 7:51 – 10:08

    Long-Term Survival and Safety Profile

    Dr. Vitoc highlights that the therapy is not merely palliative, citing patients surviving over four years due to immune memory. He emphasizes the drug's selectivity, as it only works in telomerase-positive cells, with less than 1% of normal cells expressing telomerase, resulting in low collateral damage.

Claims worth verifying

Ateganosine has a novel dual mechanism of action: telomere targeting and immunogenicity.

Unidentified speaker (speaker_2) ·0:55

How to verify: Check MAIA Biotechnology investor presentations or press releases detailing the drug's mechanism of action; verify against FDA briefing documents for ateganosine. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Telomerase is present in all normal cells in the first year of life, then goes away, and telomeres shorten with each cell division.

Unidentified speaker (UNKNOWN) ·2:04

How to verify: Verify via peer-reviewed scientific literature on telomere biology and telomerase expression in human development (e.g., Nature Reviews Cancer). For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

In cancer cells, telomerase is reactivated, granting replicative immortality.

Unidentified speaker (speaker_2) ·2:47

How to verify: Verify via scientific literature on telomerase reactivation in oncology (e.g., studies published in journals like Cancer Research). For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Ateganosine is an analog of guanosine, a building block of DNA.

Unidentified speaker (speaker_2) ·3:01

How to verify: Check MAIA Biotechnology's scientific publications or drug profile documents for chemical structure details of ateganosine. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Primary source

The drug kills 70-90% of cancer cells within 24-72 hours.

Unidentified speaker (speaker_2) ·3:31

How to verify: Verify via MAIA Biotechnology's preclinical data presentations or published studies on ateganosine's cytotoxicity timeline. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

The FDA awarded ateganosine three orphan drug designations for liver cancer, small cell lung cancer, and brain cancer.

Unidentified speaker (UNKNOWN) ·4:32

How to verify: Search FDA Orphan Drug Designation database for ateganosine (THIO) to confirm designations and indications. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Over 85% of human cancers rely on telomerase; small cell lung cancer is 100%.

Unidentified speaker (speaker_1) ·4:55

How to verify: Verify via scientific literature on telomerase prevalence in various cancer types (e.g., studies in Journal of Clinical Oncology). For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Phase Two results showed an 88% disease control rate and 17.8-month median overall survival in third-line non-small cell lung cancer.

Unidentified speaker (speaker_2) ·6:41

How to verify: Check MAIA Biotechnology's Phase Two clinical trial results presentations or press releases for specific efficacy endpoints. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Chemotherapy has a disease control rate of 25-35% and median overall survival of 5.8 months in the same setting.

Unidentified speaker (speaker_2) ·6:53

How to verify: Verify via clinical guidelines or published studies on standard of care chemotherapy outcomes for third-line non-small cell lung cancer. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

A patient survived over four years on ateganosine due to immune memory, with ten other patients crossing the two-year mark.

Unidentified speaker (speaker_2) ·8:05

How to verify: Check MAIA Biotechnology's long-term follow-up data presentations or clinical trial updates for survival statistics. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Phase Two clinical trial data in MAIA Biotechnology's SEC filings or press releases for the 88% disease control rate and 17.8-month median survival in third-line NSCLC.
  • Check FDA Orphan Drug Designation database for the specific indications: liver cancer, small cell lung cancer, brain cancer, and pediatric brain cancer.
  • Review primary literature on telomerase prevalence rates across different cancer types to validate the 85-100% claims.
  • Assess the current status of Phase Three trial enrollment and design through MAIA Biotechnology's investor presentations or clinical trial registries (e.g., ClinicalTrials.gov).
  • Investigate potential conflicts of interest or financial disclosures from Dr. Vlad Vitoc and MAIA Biotechnology regarding the interview.
  • Compare ateganosine's safety profile and mechanism of action against existing checkpoint inhibitors and standard chemotherapy regimens.
  • Look for independent peer-reviewed studies validating the immunogenic cell death and neoantigen presentation mechanism described.
  • Confirm the definition of 'disease control rate' used in the Phase Two results to ensure accurate comparison with standard of care benchmarks.
Full transcriptexpand

0:00Unidentified speaker (speaker_0): The Financial Survival Network. Now more than ever.

0:07Unidentified speaker (UNKNOWN): And

0:07Unidentified speaker (speaker_1): welcome. You are listening to and watching the Financial Survival Network. I'm your host, Carrie Lutz. You know, we always talk about financial survival. This time we're talking about survival of life. Dr. Vlad Claude Vitok with us now. And he's working on a unique

0:26Unidentified speaker (UNKNOWN): campaign.

0:26Unidentified speaker (speaker_1): cancer therapy. And so when when I'm talking here with uh Dr. Vituk on uh MAIA, Maya Biotechnology, this could present a major, major improvement in the way we treat people suffering from a variety of cancers. How does your therapy act as a primer to wake up the immune system where so many other types of standard immunotherapy have failed?

0:55Unidentified speaker (speaker_2): Yes, thank you, Kerry, for having me on your show. It's um honor to be here. So our drug ateano theme has a novel dual mechanism of action: telomere targeting and immunogenicity, training the immune system to respond to cancer.

1:12Unidentified speaker (UNKNOWN): So

1:12Unidentified speaker (speaker_2): the way this drug works, um is uh this. First you have to imagine your chromosome are usually represented uh as an X. The chromosome contains our DNA or genetic information. And at the end of the chromosome arms are the telomeres, our target.

1:31Unidentified speaker (UNKNOWN): The

1:31Unidentified speaker (speaker_2): telomeres are also made of DNA, like the chromosome, but they have a very specific function to protect the intact. integrity of the chromosome in the course of the cell division cycle. Cell divisions are always imperfect. So the objective is to translate the chromosome material from the mother cell to the daughter cell intact. But this is rarely so. So the telomere's job is to protect that process and it they take the hits and become shorter in time. Initially,

2:04Unidentified speaker (UNKNOWN): they

2:04Unidentified speaker (speaker_2): are built and maintained by an enzyme called telomerase, which is present in all normal cells in the first year of life. At about age one, telomerase goes away, and at that point the telomeres reach their maximum length. From then on, with each cell division Vision cycle, they take a hit, they become shorter and shorter, until in the old age they become

2:26Unidentified speaker (UNKNOWN): a little bit more.

2:27Unidentified speaker (speaker_2): critically short, they can no longer protect the chromosome, and mutations begin to appear. And with this, diseases of the old age, including cancers. But in cancer cells, something extraordinary happens. The enzyme telomerase is reactivated, and the cancer cells regain their ability to elongate their telomeres. and so reach a state of replicative immortality, meaning they continue to divide and the tumor grows in the otherwise aging body.

3:00Unidentified speaker (UNKNOWN): This

3:01Unidentified speaker (speaker_2): is where ateganosin comes in. Atiganosine, which is an analog of guanosine, one of the building blocks of the DNA of the telomeres, it's uh picked up by telomerase, placed in the structure of the telomere. This creates a faulty unstable structure.

3:19Unidentified speaker (UNKNOWN): The

3:20Unidentified speaker (speaker_2): telomeres collapse, the DNA unwind, and the cancer cells die.

3:25Unidentified speaker (UNKNOWN): This

3:25Unidentified speaker (speaker_2): process is fast and efficient. It happens in 24 to 72 hours.

3:30Unidentified speaker (UNKNOWN): And

3:31Unidentified speaker (speaker_2): it kills directly 70 to 90 percent of the cancer cells. Then follows the second mechanism. of action.

3:40Unidentified speaker (UNKNOWN): Of

3:40Unidentified speaker (speaker_2): the telomeric fragments, ateanosine forms micronuclei, small, incomplete nuclei that transport these fragments and present them to the immune cells, becoming neoantigens in the immune pathways that trigger an immune response so efficient that if you follow ateganosin ateganosene with an uh immune therapy, such as the checkpoint inhibitor, you then see complete response, no recurrence, and anti-tumor immune memory. We have seen this uh curative effect in preclinical setting in multiple tumor types, in lung cancer, in colorectal, in liver cancer, in uh small cell line cancer, and brain cancers, in combination with different checkpoint inhibitors or even with radiation therapy in the case of brain cancer.

4:32Unidentified speaker (UNKNOWN): And

4:32Unidentified speaker (speaker_2): the data was so convincing that when we presented it to the FDA, the FDA awarded Ateganosine three orphan drug designations out of three applications for liver cancer, for small cell lung cancer, and for brain cancer.

4:49Unidentified speaker (UNKNOWN): And

4:49Unidentified speaker (speaker_2): also a rare pediatric. disease designation for children's brain cancers.

4:54Unidentified speaker (UNKNOWN): So

4:54Unidentified speaker (speaker_2): very strong.

4:55Unidentified speaker (speaker_1): If I have this right, uh over 85% of the cancers, human cancers rely on the enzyme telomerase to keep dividing endlessly. Do I have that right?

5:08Unidentified speaker (speaker_2): Yes, that is true. And um in some tumor types, it's a 100% hundred percent of the cells, like in small cell lung cancer, for instance.

5:15Unidentified speaker (UNKNOWN): Um

5:15Unidentified speaker (speaker_2): non-small cell lung cancer is eighty-five percent,

5:18Unidentified speaker (UNKNOWN): uh

5:18Unidentified speaker (speaker_2): colorectal ninety, liver ninety. Uh on the low end, uh you have uh neuroblastomas and sarcomas, rare tumor types. They exp uh they are at around 40 percent the memory expression.

5:33Unidentified speaker (UNKNOWN): All

5:33Unidentified speaker (speaker_2): of them very big numbers. So th this is one of those rare fundamental mechanisms of action that pertain to many, many almost every type of cancer to a great extent. And um you don't find something like this every day. This is something that comes around in 30, 40 years. That I haven't seen something like this since the launch of Gitruda, the um anti PD1 inhibitor by Merck, that's now the most successful drug in the world.

6:00Unidentified speaker (UNKNOWN): And

6:00Unidentified speaker (speaker_1): you've you're in phase two trials now. if I understand that correctly, and you've gotten a 90

6:07Unidentified speaker (UNKNOWN): plus

6:07Unidentified speaker (speaker_1): percent disease control rate and 17.8 month median overall survival rate, and that number is going up, correct?

6:16Unidentified speaker (UNKNOWN): Yes,

6:16Unidentified speaker (speaker_2): we have amazing results in the phase two. We are now enrolling in the phase three. We are actually almost a third of the way enrolled in the phase three, which is the last phase for commercial approval. But in the data that you cite comes from the phase two, which is now completed. Um, disease control rates represent the percentage of patients who do not have a progression of the disease at the time of the first scan.

6:40Unidentified speaker (UNKNOWN): So

6:41Unidentified speaker (speaker_2): this is how the doctor and the patient can tell the the drug and/or And or the at regimen in this in this case works.

6:48Unidentified speaker (UNKNOWN): Um

6:48Unidentified speaker (speaker_2): we've seen 88% disease control rates. in the setting.

6:52Unidentified speaker (UNKNOWN): Um,

6:53Unidentified speaker (speaker_2): and uh to give you a comparison, chemotherapy, which is currently the standard of care for the setting, has disease control rates of 25 to 35 percent.

7:03Unidentified speaker (UNKNOWN): So

7:03Unidentified speaker (speaker_2): we are at three times the disease control compared to standard of care.

7:08Unidentified speaker (UNKNOWN): And

7:08Unidentified speaker (speaker_2): in terms of survival, disease control rates are also important because they are the best pre pre-early early predictor for overall. survival advantage. And uh for overall survival, we have seen median overall survival of 17.8 months versus 5.8 months with chemotherapy. And these are patients in third line of therapy with non-small cell lung cancer. They've already progressed through two lines, through immune therapy and to chemotherapy.

7:35Unidentified speaker (UNKNOWN): And

7:35Unidentified speaker (speaker_2): now they're in third line, and this is where they their options are very, very limited.

7:40Unidentified speaker (UNKNOWN): Um,

7:40Unidentified speaker (speaker_2): so we're tripling that. So I've never seen a drug going from phase two to phase three with a triple effect compared to standard of care in any tumor attacks.

7:51Unidentified speaker (speaker_1): Most of the chemo that I've seen, a lot of it is palliative, right? This

7:56Unidentified speaker (UNKNOWN): is

7:56Unidentified speaker (speaker_1): not a palliative therapy. It's not just there to uh make the patient more comfortable or easier. to deal with the disease here. It's actually reversing it.

8:05Unidentified speaker (speaker_2): Yes, we have very long-term survival is the um uh record holder now of our patients is pushing on four years of survival since initiation of the treatment in the trial. The trial protocol provides for two years up to two years of treatment. And this patient completed two years of treatment and ever since, without any therapy, just on the basis of immune memory, because of atiganosine, continues to do very well. The second longest living patient

8:36Unidentified speaker (UNKNOWN): is

8:37Unidentified speaker (speaker_2): past three years as well. And we have now ten other patients that have crossed the two year mark as well. So a lot of long term survivors here. You

8:45Unidentified speaker (speaker_1): know, somehow you found the magic bullet. Uh some people would call it a etagonousene. etagonosine, THIO. We'll call it THIO, it's easier. And basically it tricks these telomerase into uh you know messing up their DNA, I guess, and uh shattering them.

9:04Unidentified speaker (speaker_2): Yeah, um this mechanism, uh so it uh inhibition of telomerase has been tried. Uh we're not but we're not inhibiting telomerase, we are using telomerase. Uh so So it is it is in the same um biology direction, but in the opposite sense. You know, it's like uh we are using telomerase. Our drug, ateganosene, will only work in cancer in cells that are telomerase positive. And 85% of cancer cells are. Under 1% of normal cells are telomerase positive. So the collateral damage. is very, very low.

9:40Unidentified speaker (speaker_1): The name of the drug is etagonosine. T-H-I-O. It was an honor to have you on the uh show, Doctor. And uh we'll look forward to speaking with you again later and getting updates.

9:51Unidentified speaker (speaker_2): Thank you very much, Kerry. It's a pleasure to be here with

9:54Unidentified speaker (UNKNOWN): you. The

10:01Unidentified speaker (speaker_0): Financial Survival Network.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights